SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-024854
Filing Date
2020-05-13
Accepted
2020-05-13 08:02:28
Documents
58
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 Q1-2020 10Q alna-10q_20200331.htm 10-Q 1702217
2 EX-31.1 alna-ex311_7.htm EX-31.1 16661
3 EX-31.2 alna-ex312_6.htm EX-31.2 16700
4 EX-32.1 alna-ex321_8.htm EX-32.1 10192
  Complete submission text file 0001564590-20-024854.txt   4647682

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT alna-20200331.xml EX-101.INS 742690
6 XBRL TAXONOMY EXTENSION SCHEMA alna-20200331.xsd EX-101.SCH 36101
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE alna-20200331_cal.xml EX-101.CAL 32928
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE alna-20200331_def.xml EX-101.DEF 121865
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE alna-20200331_lab.xml EX-101.LAB 300272
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alna-20200331_pre.xml EX-101.PRE 234258
Mailing Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462
Business Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462 617-467-4577
Allena Pharmaceuticals, Inc. (Filer) CIK: 0001624658 (see all company filings)

IRS No.: 452729920 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38268 | Film No.: 20871108
SIC: 2836 Biological Products, (No Diagnostic Substances)